Comparison of neutralizing and hemagglutination-inhibiting antibody responses to influenza A virus vaccination of human immunodeficiency virus-infected individuals.
A neutralization enzyme immunoassay (N-EIA) was used to determine the neutralizing serum antibody titers to influenza A/Taiwan/1/86 (H1N1) and Beijing/353/89 (H3N2) viruses after vaccination of 51 human immunodeficiency virus (HIV) type 1-infected individuals and 10 healthy noninfected controls against influenza virus infection. Overall, the N-EIA titers correlated well with the hemagglutination-inhibition (HAI) titers that were observed in the same samples in a previous study (F. P. Kroon, J. T. van Dissel, J. C. de Jong, and R. van Furth, AIDS 8:469-476,1994). The N-EIA appeared to be more sensitive than the HAI test. Significantly more fourfold or higher rises in N-EIA titer and higher mean N-EIA titers occurred in HIV-infected individuals with > or =200 CD4+ cells per microl than in those with <200 CD4+ cells per microl.
Benne
C A
CA
Eijkman-Winkler Laboratory of Medical Microbiology, University Hospital Utrecht, The Netherlands.
Kroon
F P
FP
Harmsen
M
M
Tavares
L
L
Kraaijeveld
C A
CA
De Jong
J C
JC
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D019067:Antibody-Dependent Enhancement; D003627:Data Interpretation, Statistical; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007124:Immunoenzyme Techniques; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000627:therapeutic use*; D008297:Male; D008722:Methods; D008875:Middle Aged; D009500:Neutralization Tests; D013997:Time Factors; D014611:Vaccination
D000914:Antibodies, Viral; D007252:Influenza Vaccines